Altimmune Stock News

Equities analysts forecast that Altimmune, Inc. (NASDAQ:ALT) will report earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Altimmunes earnings, with estimates ranging from ($0.89) to ($0.44). Altimmune reported earnings per share of ($0.17) during the same quarter last year, which suggests a []

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Direct

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmunes 2018 Inducement Grant Plan, as a material inducement to employ Richard Eisenstadt as Altimmunes Chief Financial Officer effective December 31, 2021. The equity awards were approved on December 9, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. Mr. Eisenstadt succeeds Will Brown, who is leaving Altimmune to pursue other opportunities.

Altimmune Inc (NASDAQ: ALT) has announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. These are the details.

Altimmune Inc. (NASDAQ:ALT)s traded shares stood at 0.44 million during the last session, with the companys beta value hitting 1.72. At the close of trading, the stocks price was $9.42, to imply a decrease of -2.08% or -$0.2 in intraday trading. The ALT shares 52-week high remains $24.61, putting it -161.25% down since that peak Altimmune Inc. (NASDAQ: ALT) Friday The Stock Is Down -161.25% Since The Lows, What Comes Next? Read More »

Analysts forecast that Altimmune, Inc. (NASDAQ:ALT) will announce ($0.64) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Altimmunes earnings, with estimates ranging from ($0.89) to ($0.44). Altimmune reported earnings of ($0.17) per share during the same quarter last year, which suggests a negative year-over-year growth []

Northern Trust Corp grew its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 266.6% during the second quarter, HoldingsChannel reports. The firm owned 332,290 shares of the companys stock after buying an additional 241,637 shares during the period. Northern Trust Corps holdings in Altimmune were worth $3,274,000 as of its most recent SEC filing. Other []

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will b

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will be presenting virtually at the following conferences:

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be pr

Wall Street brokerages forecast that Altimmune, Inc. (NASDAQ:ALT) will post $150,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Altimmunes earnings, with the highest sales estimate coming in at $200,000.00 and the lowest estimate coming in at $100,000.00. Altimmune reported sales of $2.31 million in the same []

Altimmune, Inc. (NASDAQ:ALT) Piper Sandler lowered their FY2021 earnings per share (EPS) estimates for shares of Altimmune in a research note issued on Wednesday, November 10th. Piper Sandler analyst Y. Rahimi now expects that the company will post earnings per share of ($2.48) for the year, down from their previous forecast of ($1.68). Piper []

Altimmune, Inc. (NASDAQ:ALT) Equities research analysts at Piper Sandler dropped their FY2021 EPS estimates for shares of Altimmune in a report issued on Wednesday, November 10th. Piper Sandler analyst Y. Rahimi now forecasts that the company will post earnings of ($2.48) per share for the year, down from their prior forecast of ($1.68). Piper []